Form 4: Director David Shedlarz Adjusts Teladoc Equity Holdings

Teladoc Health director David Shedlarz acquired 29,986 shares via RSU vesting and was granted 30,441 new restricted stock units.

Summary

• Director David L. Shedlarz acquired 29,986 shares of Teladoc Health (TDOC) common stock on May 20, 2026, through the vesting of restricted stock units (RSUs).
• Following the transaction, the director holds a total of 61,266 shares of common stock.
• On May 21, 2026, the director was granted an additional 30,441 restricted stock units.
• The new RSU grant is scheduled to vest on the earlier of May 21, 2027, or the day before the 2027 annual meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting routine director compensation and equity management.

Positives

• Director maintains a significant equity stake of 61,266 shares, aligning interests with shareholders.

Negatives

• None identified; this is a standard equity compensation disclosure.

Risks

• Future vesting of the 30,441 RSUs is contingent upon continued service or specific corporate events such as a change of control.

Future Outlook

The director holds 30,441 unvested restricted stock units that will vest in May 2027, subject to continued service or specific change-in-control provisions.

Industry Context

StockSavvy.ai notes that director equity grants are standard practice in the telehealth sector to ensure long-term retention and alignment with corporate performance goals.

Comparison to Industry Standards

• The equity compensation structure is consistent with standard corporate governance practices for S&P 400/500 companies.
• The one-for-one conversion of RSUs to common stock is standard for executive and director compensation plans.

Stakeholder Impact

• Minimal impact; reflects standard director compensation rather than a change in strategic direction or financial health.

Next Steps

• Vesting of 30,441 restricted stock units on or before May 21, 2027.

Key Dates

Keywords

Teladoc Health, TDOC, Insider Trading, Form 4, Equity Compensation, Director Compensation